Jim Cramer’s 5 Stock Calls, Including Alphabet and Eli Lilly, and Possible Opportunities

4. Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer mentioned the stock while discussing the woes of the healthcare industry, as he said:

Next worst is healthcare. Oh, this group has just been annihilated. I’ve never seen it trading this bad ever. There are myriad problems. Federal government’s been putting pressure on drug pricing. The FDA is not exactly friendly. Investors are worried about competition, especially for the GLP-1 formulations. Now, it’s easy for me to suggest you Eli Lilly as it has multiple versions of GLP-1 drugs including a new one that may be the first that sheds fat without muscle…

Notice this version has not been approved for any of these things. But I think that if approved, it’ll ultimately give Lilly the unassailable knockout punch against Novo Nordisk because it’s got fat busting without muscle crunching. The worry I have with this one, though, it’s the same unreliable fellow shareholders who own… tech also own Lilly.

Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic conditions.